Polyrizon (PLRZ) Retained Earnings (2023 - 2025)
Polyrizon's (PLRZ) quarterly Retained Earnings came in at $29.4 million in Q4 2025, up 183.95% YoY from $10.4 million in Q4 2024, and up 24.46% on a QoQ basis from $23.6 million in Q2 2025.
Polyrizon (PLRZ) Retained Earnings (2023 - 2025) Analysis & Trends
Polyrizon (PLRZ) has 3 years of Retained Earnings data on file, last reported at $29.4 million in Q4 2025.
- Quarterly Retained Earnings rose 183.95% year-over-year to $29.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29.4 million (up 183.95% YoY) and the FY2025 annual result came in at $29.4 million, up 183.95% from the prior year.
- Retained Earnings rose to $29.4 million in Q4 2025, from $23.6 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $29.4 million in Q4 2025 to a low of $3.5 million in Q4 2023.
- A 3-year average of $16.7 million and a median of $17.0 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings soared 193.59% — and 2025, when it surged 183.95%.
- Tracing PLRZ's Retained Earnings over 3 years: stood at $3.5 million in 2023, then jumped by 193.59% to $10.4 million in 2024, then surged by 183.95% to $29.4 million in 2025.
- The last three Retained Earnings figures came in at $29.4 million (Q4 2025), $23.6 million (Q2 2025), and $10.4 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Polyrizon | 7.27 Mn | -4.22 Mn | - | 29.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 29.40 Mn |
| Jun 30, 2025 | 23.62 Mn |
| Dec 31, 2024 | 10.35 Mn |
| Dec 31, 2023 | 3.53 Mn |